Premium
Practical Ethics: Establishing a Pathway to Benefit for Complex Pharmacogenomic Tests
Author(s) -
Haga SB,
Burke W
Publication year - 2011
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1038/clpt.2011.71
Subject(s) - abacavir , pharmacogenomics , medicine , intensive care medicine , risk analysis (engineering) , pharmacology , family medicine , human immunodeficiency virus (hiv) , viral load , antiretroviral therapy
Pharmacogenomic tests offer a promising strategy to improve the safety and efficacy of drug treatment. Compelling examples, such as HLA‐B*5701 testing to identify patients at risk for abacavir‐associated hypersensitivity, are already changing clinical care. However, the level of evidence required to establish clinical utility is often the subject of debate. Determining the most efficient and effective pathway to benefit for a given test is therefore both a practical and an ethical concern. Clinical Pharmacology & Therapeutics (2011) 90 1, 25–27. doi: 10.1038/clpt.2011.71